Novartis AG ADR (NVS)vsPureTech Health PLC (PRTC)
NVS
Novartis AG ADR
$158.83
-0.24%
HEALTHCARE · Cap: $290.96B
PRTC
PureTech Health PLC
$17.42
0.00%
HEALTHCARE · Cap: $419.90M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1216749% more annual revenue ($56.69B vs $4.66M). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PRTC
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.7%
Fair Value
$92.54
Current Price
$158.83
$66.29 premium
Intrinsic value data unavailable for PRTC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Earnings expanding 61.5% YoY
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -30.8% — below average capital efficiency
Revenue declined 38.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bull Case : PRTC
The strongest argument for PRTC centers on Price/Book, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : PRTC
The primary concerns for PRTC are Market Cap, Profit Margin, Return on Equity.
Key Dynamics to Monitor
PRTC carries more volatility with a beta of 0.79 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 30/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →PureTech Health PLC
HEALTHCARE · BIOTECHNOLOGY · USA
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops and markets drugs for inflammatory, fibrotic and immune, intractable, lymphatic and gastrointestinal, neurological and neuropsychological cancers and other diseases in the United States. The company is headquartered in Boston, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?